Document is current

Article History

Accepted: 27 March 2023

First Online: 3 May 2023

Declarations

:

: Medical writing assistance was funded by AstraZeneca Pharmaceuticals. In March 2019, AstraZeneca entered into a global development and commercialization collaboration agreement with Daiichi Sankyo for trastuzumab deruxtecan (T-DXd; DS-8201).

: Both authors received nonfinancial assistance (assistance with outline preparation and podcast development) from ArticulateScience, LLC, which was funded by AstraZeneca Pharmaceuticals. Additional disclosures are as follows: <i>Aditya Bardia</i> has received grants and consulting fees from Genentech, Novartis, Pfizer, Merck, Sanofi, Radius Health, Immunomedics/Gilead, Daiichi Sankyo/AstraZeneca, Eli Lilly, and Foundation Medicine. <i>Giuseppe Viale</i> has received consulting fees from AstraZeneca and Agilent; advisory board fees from Daiichi Sankyo, Roche, and MSD Oncology during the conduct of the study; and grants from AstraZeneca, all outside the submitted work.

: Data sharing is not applicable, as no data sets were generated or analyzed.

: Not applicable.

: Not applicable.

: Not applicable.

: Not applicable.

: <i>Aditya Bardia:</i> Conceptualization; writing—review and editing. <i>Giuseppe Viale:</i> Conceptualization; writing—review and editing.